SCHEMBL6098683

SCHEMBL6098683

[CH2]Cc1ccc(-n2nc(C)c(-c3ccc(O)cc3)c2C)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.56
RAB9A P51151 5/20 0.49
NPC1 O15118 4/20 0.49
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
NPSR1 Q6W5P4 3/20 0.41
CYP2D6 P10635 2/20 0.41
MAPK1 P28482 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
AR P10275 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TP53 P04637 3/20 0.37
LMNA P02545 2/20 0.37
ESR1 P03372 2/20 0.37
GMNN O75496 1/20 0.37
USP2 O75604 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095453 0.89 CYP1A2 (0.59) CYP1A2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL6096730 0.86 CYP1A2 (0.76) CYP1A2RAB9ANPC1SMN1; SMN2CYP2D6
SCHEMBL6096261 0.86 CYP1A2 (0.56) CYP1A2RAB9ANPC1SMN1; SMN2CYP2D6
SCHEMBL6097575 0.86 CYP1A2 (0.56) CYP1A2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL6096209 0.84 CYP1A2 (0.49) CYP1A2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL6098356 0.84 CYP1A2 (0.54) CYP1A2RAB9ANPC1SMN1; SMN2CYP2D6
SCHEMBL6097358 0.82 CYP1A2 (0.50) CYP1A2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL6096068 0.82 CYP1A2 (0.52) CYP1A2MAPTSMN1; SMN2NPSR1KDM4E
SCHEMBL6097652 0.80 CYP1A2 (0.50) CYP1A2MAPTCYP2D6ARALDH1A1
SCHEMBL6097637 0.80 CYP1A2 (0.59) CYP1A2RAB9ANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001917-B2 Pyrazole compounds as anti-inflammatory and analgesic agents WARNER LAMBERT COMPANY LLC (US) 2006-02-21 US disclosed
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents HIRANO MISATO (JP) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents PTGER1, PTGS1, PTGIR CYP1A2 670/4885RAB9A 3940/4885NPC1 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.